Personalis Inc. Raises Full-Year Revenue Guidance
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
- Latest
- Trending
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
Bio-Techne shows resilience with strategic growth in diagnostics despite fiscal year challenges and market declines.
AdvanceTEC leads the biopharma industry with innovative prefabrication methods, enhancing efficiency and speed in cleanroom construction.
Veracyte's Q2 revenue surged 27% to $114.4M, fueled by strong demand for genomic tests. Full-year guidance raised to $432M-$438M.
Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
Wake Tech breaks ground on a $60M Advanced Technology Center in Wendell, offering state-of-the-art biopharma and manufacturing training. Opens spring ...
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.